LDS/Medical Tests/Alpha-L-Iduronidase (IDUA) Gene Mutation Analysis, Full Sequencing

Alpha-L-Iduronidase (IDUA) Gene Mutation Analysis, Full Sequencing

Mucopolysaccharidosis type I (MPS I) is an autosomal recessive lysosomal storage disorder resulting from a deficiency of α-L-iduronidase (IDUA). The IDUA gene encodes for an enzyme called alpha-L-iduronidase, which is essential for the breakdown of large sugar molecules called glycosaminoglycans (GAGs). Through a process called hydrolysis, alpha-L-iduronidase uses water molecules to break down a molecule known as unsulfated alpha-L-iduronic acid, which is present in two GAGs called heparan sulfate and dermatan sulfate. Alpha-L-iduronidase is located in lysosomes, compartments within cells that digest and recycle different types of molecules.

Based on clinical features and enzyme deficiency, MPS I has traditionally been divided into three subtypes: a severe subtype (Hurler syndrome), an intermediate subtype (Hurler–Scheie syndrome), and an attenuated subtype (Scheie syndrome). As there is considerable overlap between these subtypes and there are no easily measured biochemical differences, individuals are best described as having either severe or attenuated MPS I.

Patients with the severe form (Hurler) have early manifestations of the disease that includes skeletal deformities, coarse facial features, corneal clouding, macrocephaly, hydrocephalus, hepatosplenomegaly, cardiac abnormalities, hearing loss, and respiratory tract infections and severe intellectual dysfunction. Death, typically caused by cardiorespiratory failure, usually occurs within the first ten years of life. Features of Hurler-Scheie syndrome and Scheie syndrome (attenuated MPS I) typically appear between 3 to 10 years of age with corneal clouding, cardiac abnormalities, moderate-to-severe hearing loss, and progressive pulmonary disease. Significant disability from progressive joint manifestations is common in MPS I.

  • Diagnostic confirmation of mucopolysaccharidosis type I
  • Carrier testing in family members of the affected patient
  • For the prenatal diagnosis in at-risk pregnancies
  • For pre-implantation genetic diagnosis of MPS I.
  • To assist with prognosis, clinical management and surveillance for disease features based on the genetic variant involved.
Depends on the variants (heterozygous or homozygous), individuals can be carrier or affected with mucopolysaccharidosis type I (MPS-I).

No reportable variants were identified

Sequence analysis by next generation sequencing or bi-directional sequencing. IDUA gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

Whole blood, skin biopsy, cultured cells.

Stability (blood)

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
Urinary glycosaminoglycans (GAGs - Dermatan sulfate, heparan sulfate), α-L-iduronidase (IDUA) enzyme activity, comprehensive lysosomal storage disorder gene mutation panel, comprehensive mucopolysaccharidosis (MPS) gene panel, peripheral blood smear review for Alder-Reilly granules in leukocytes.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Clin Chim Acta. 2014; 430: 24-7. [PMID: 24389097]
  • Metab Brain Dis. 2012;27: 121-9. [PMID: 22527994]
  • Orphanet J Rare Dis. 2008;3: 24. [PMID: 18796143]
  • Mol Genet Metab. 2007;91: 37-47. [PMID: 17336562]
  • Genet Med. 2003;5: 286-94. [PMID: 12865757]
  • Mol Genet Metab. 1998 Oct;65(2):174-80. [PMID: 9787109]
  • Genetics Home Reference. Available: https://ghr.nlm.nih.gov/condition/mucopolysaccharidosis-type-i#
  • GeneReviews® [Internet]. Available at:https://www.ncbi.nlm.nih.gov/books/NBK1162/